Clinical trial
A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients
NCT06412471 is registered in ClinicalTrials.gov with Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients
- Lead sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- July 26, 2024
- Completion date
- August 31, 2025
- Enrollment
- 235 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
first-line advanced nsclc patients